ERT pumps up cardiac safety solutions with iCardiac acquisition
iCardiac Technologies, Inc. is a centralized core laboratory for cardiac safety, respiratory, and electronic clinical outcome assessment (eCOA) clinical trial services. The Rochester, NY-based company serves eight of the top 10 global pharmaceutical companies.
The acquisition, financial terms of which were not disclosed, expands ERT’s portfolio of cardiac safety solutions, according to the company.
James Corrigan, president and CEO of ERT commented in the press release: “The iCardiac acquisition expands ERT’s ability to deliver solutions that help our customers create novel therapies in the fastest, most efficient and cost-effective manner possible.”
“This includes greater flexibility in early phase trials, as well as a stronger partner who can support the entire development lifecycle,” he said.
ERT is not providing any additional comment at this time.
Cardiac safety solutions
iCardiac’s eCOA platform, QPoint – which it announced in February – can measure clinical outcome assessments from patients at home or during site visits. The release represented a major step forward for the company, iCardiac president and CEO Alex Zapesochny told us at the time.
“An important differentiator is our study setup simulator, which enables the eCOA vendor to efficiently and interactively create, review and test a study questionnaire in real time,” he said.
The acquisition of iCardiac follows ERT’s purchase of Biomedical Systems, a global provider of cardiac safety and respiratory data collection solutions, in September.
According to the company, the acquisition enables it to expand its ability “to reduce customer risk and uncertainty when imaging, cardiac safety and respiratory data collection are required.”
ERT also acquired an imaging solution, ImageIQ, from Cleveland Clinic in May.
